CN111693621B - 一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 - Google Patents
一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 Download PDFInfo
- Publication number
- CN111693621B CN111693621B CN202010476340.7A CN202010476340A CN111693621B CN 111693621 B CN111693621 B CN 111693621B CN 202010476340 A CN202010476340 A CN 202010476340A CN 111693621 B CN111693621 B CN 111693621B
- Authority
- CN
- China
- Prior art keywords
- serum
- pancreatic cancer
- peptide
- abundance
- establishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 172
- 210000002966 serum Anatomy 0.000 title claims abstract description 169
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 135
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 134
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 134
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 134
- 238000003745 diagnosis Methods 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 65
- 238000001514 detection method Methods 0.000 claims abstract description 55
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims abstract description 31
- 206010033649 Pancreatitis chronic Diseases 0.000 claims abstract description 31
- 238000004458 analytical method Methods 0.000 claims abstract description 19
- 239000000090 biomarker Substances 0.000 claims abstract description 11
- 238000005516 engineering process Methods 0.000 claims abstract description 8
- 238000005070 sampling Methods 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 23
- 238000001819 mass spectrum Methods 0.000 claims description 22
- 238000012216 screening Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 238000012549 training Methods 0.000 claims description 18
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 17
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 17
- 238000012545 processing Methods 0.000 claims description 17
- 101000974345 Homo sapiens Nuclear receptor coactivator 7 Proteins 0.000 claims description 16
- 102100022930 Nuclear receptor coactivator 7 Human genes 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 15
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 14
- 102100030942 Apolipoprotein A-II Human genes 0.000 claims description 14
- 102000004506 Blood Proteins Human genes 0.000 claims description 14
- 108010017384 Blood Proteins Proteins 0.000 claims description 14
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 14
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 108010024284 Apolipoprotein C-II Proteins 0.000 claims description 13
- 102100039998 Apolipoprotein C-II Human genes 0.000 claims description 13
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 13
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 13
- 102100024340 Contactin-4 Human genes 0.000 claims description 12
- 101000909504 Homo sapiens Contactin-4 Proteins 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- 238000007477 logistic regression Methods 0.000 claims description 8
- 238000007405 data analysis Methods 0.000 claims description 7
- 239000007791 liquid phase Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000011160 research Methods 0.000 claims description 6
- 238000012795 verification Methods 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- 238000013473 artificial intelligence Methods 0.000 claims description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000003643 water by type Substances 0.000 claims description 5
- 238000000540 analysis of variance Methods 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000004422 calculation algorithm Methods 0.000 claims description 3
- 238000013375 chromatographic separation Methods 0.000 claims description 3
- 238000000132 electrospray ionisation Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 238000004896 high resolution mass spectrometry Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000000925 erythroid effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 11
- 238000001228 spectrum Methods 0.000 abstract description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 238000003759 clinical diagnosis Methods 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 3
- 101000609413 Homo sapiens Inter-alpha-trypsin inhibitor heavy chain H4 Proteins 0.000 description 3
- 102100039457 Inter-alpha-trypsin inhibitor heavy chain H4 Human genes 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 2
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 2
- 108091005903 Hemoglobin subunit delta Proteins 0.000 description 2
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 2
- GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O GACDQMDRPRGCTN-KQYNXXCUSA-N 0.000 description 1
- 101710094518 4-aminobutyrate aminotransferase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032401 Charged multivesicular body protein 2a Human genes 0.000 description 1
- 101150076092 Chmp2a gene Proteins 0.000 description 1
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100035300 Cystine/glutamate transporter Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100030987 E3 SUMO-protein ligase PIAS4 Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 1
- 101000583450 Homo sapiens E3 SUMO-protein ligase PIAS4 Proteins 0.000 description 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 1
- 101001006909 Homo sapiens Kinetochore-associated protein 1 Proteins 0.000 description 1
- 101001019367 Homo sapiens Mitofusin-1 Proteins 0.000 description 1
- 101000766826 Homo sapiens Protein CIP2A Proteins 0.000 description 1
- 101000730612 Homo sapiens Puratrophin-1 Proteins 0.000 description 1
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 description 1
- 101000976244 Homo sapiens Zinc finger protein 804B Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100028394 Kinetochore-associated protein 1 Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100034715 Mitofusin-1 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102100028634 Protein CIP2A Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100032590 Puratrophin-1 Human genes 0.000 description 1
- 108091006241 SLC7A11 Proteins 0.000 description 1
- 102100022332 Sharpin Human genes 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100024250 Ubiquitin carboxyl-terminal hydrolase CYLD Human genes 0.000 description 1
- 102100023869 Zinc finger protein 804B Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002546 full scan Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000012567 pattern recognition method Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010088972 sharpin Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8696—Details of Software
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Gastroenterology & Hepatology (AREA)
- Library & Information Science (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010476340.7A CN111693621B (zh) | 2020-05-29 | 2020-05-29 | 一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010476340.7A CN111693621B (zh) | 2020-05-29 | 2020-05-29 | 一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111693621A CN111693621A (zh) | 2020-09-22 |
CN111693621B true CN111693621B (zh) | 2022-08-23 |
Family
ID=72478927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010476340.7A Active CN111693621B (zh) | 2020-05-29 | 2020-05-29 | 一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111693621B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113917149B (zh) * | 2021-09-30 | 2024-05-24 | 江苏扬新生物医药有限公司 | 凝溶胶蛋白检测物在制备子宫癌评估检测试剂中的应用 |
CN116626297B (zh) * | 2023-07-24 | 2023-10-27 | 杭州广科安德生物科技有限公司 | 一种用于胰腺癌检测的***及其试剂或试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107942074A (zh) * | 2017-11-22 | 2018-04-20 | 南宁科城汇信息科技有限公司 | 一种建立肝癌与正常人诊断模型及肝癌与慢性肝病的诊断模型 |
CN109884302A (zh) * | 2019-03-14 | 2019-06-14 | 北京博远精准医疗科技有限公司 | 基于代谢组学和人工智能技术的肺癌早期诊断标志物及其应用 |
CN110646554A (zh) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10006925B2 (en) * | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
-
2020
- 2020-05-29 CN CN202010476340.7A patent/CN111693621B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107942074A (zh) * | 2017-11-22 | 2018-04-20 | 南宁科城汇信息科技有限公司 | 一种建立肝癌与正常人诊断模型及肝癌与慢性肝病的诊断模型 |
CN109884302A (zh) * | 2019-03-14 | 2019-06-14 | 北京博远精准医疗科技有限公司 | 基于代谢组学和人工智能技术的肺癌早期诊断标志物及其应用 |
CN110646554A (zh) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用 |
Non-Patent Citations (1)
Title |
---|
Standardized Peptidome Profiling of Human Serum for the Detection of Pancreatic Cancer;Edgar Zapico-Muñiz 等;《Pancreas》;20101130;第39卷(第8期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN111693621A (zh) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marx et al. | Proteomics and metabolomics for AKI diagnosis | |
CN108414660B (zh) | 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用 | |
CN111896651B (zh) | 一种白眉蝮蛇蛇毒类凝血酶特征多肽及其应用 | |
CN111896652B (zh) | 一种蛇毒类凝血酶的定量检测方法 | |
WO2023082820A1 (zh) | 用于肺腺癌诊断的标志物及其应用 | |
CN111693621B (zh) | 一种基于血清肽的胰腺癌诊断模型的建立方法及其应用 | |
CN113156018B (zh) | 一种肝胆疾病诊断模型的建立方法及诊断*** | |
CN113960312A (zh) | 用于肺部良恶性结节诊断的血清代谢标志物及其应用 | |
WO2011087803A1 (en) | Assay for monitoring parathyroid hormone (pth) variants by tandem mass spectrometry | |
WO2023083197A1 (zh) | 用于肺癌诊断或监测的代谢标志物及其筛选方法和应用 | |
CN114935619A (zh) | 检测水溶性维生素的方法和试剂盒 | |
CN109900841B (zh) | 一种同时测定血浆中氨基糖苷类抗生素药物浓度的hplc-ms/ms方法 | |
CN108020669B (zh) | 尿液骨桥蛋白及其多肽片段在肺腺癌中的应用 | |
CN114878723B (zh) | 快速诊断多发性骨髓瘤的代谢标志物及应用 | |
CN108020668A (zh) | 尿液sh3结构域谷氨酸富集样蛋白3蛋白及其多肽片段在肺腺癌中的应用 | |
CN108020667A (zh) | 尿液免疫球蛋白κ链C区蛋白及其多肽片段在肺腺癌中的应用 | |
CN116754772A (zh) | 老年痴呆早期诊断外周血蛋白标志物、应用及辅助诊断*** | |
CN109061179B (zh) | 氨基酸联合因子在构建结直肠癌血液学诊断模型中的应用 | |
CN114563504B (zh) | 一种测定血浆中游离醛固酮含量的方法及试剂盒 | |
CN112162049B (zh) | 一种非诊断目的检测尿液中肌氨酸的方法 | |
CN114705782B (zh) | 用于诊断或监测结直肠癌的血浆代谢标志物组合及应用 | |
CN111624264B (zh) | 一种用于早期检测移植肾急性排异的代谢组合物、筛选方法及应用 | |
CN114137192B (zh) | 7-甲基黄嘌呤作为检测靶点在制备2型糖尿病高危个体筛查试剂盒中的应用 | |
KR101912377B1 (ko) | 폐암감별진단용 바이오마커 및 이를 이용한 폐암감별진단용 정보제공 방법 | |
Fan et al. | Proteonano coupled with Orbitrap Astral: A robust and standardized workflow for large-cohort clinical plasma proteomics studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cui Wei Inventor after: Chen Feng Inventor after: Dai Xudong Inventor after: Lin Kai Inventor after: Tian Yu Inventor after: Wang Guan Inventor before: Cui Wei Inventor before: Chen Feng Inventor before: Dai Xudong Inventor before: Lin Kai Inventor before: Tian Yu Inventor before: Wang Guan |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |